The JAK2 pathway is activated in idiopathic pulmonary fibrosis.

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal fibrotic disorder, with no curative therapies. The signal transducer and activator of transcription 3 (STAT3) protein is activated in lung fibroblasts and alveolar type II cells (ATII), thereby contributing to lung fibrosis in IPF. Although activation of Janus kinase 2 (JAK2) has been implicated in proliferative disorders, its role in IPF is unknown. The aim of this study was to analyze JAK2 activation in IPF, and to determine whether JAK2/STAT3 inhibition is a potential therapeutic strategy for this disease. METHODS AND RESULTS: JAK2/p-JAK2 and STAT3/pSTAT3 expression was evaluated using quantitative real time-PCR, western blotting, and immunohistochemistry. Compared to human healthy lung tissue (n = 10) both proteins were upregulated in the lung tissue of IPF patients (n = 12). Stimulating primary ATII and lung fibroblasts with transforming growth factor beta 1 or interleukin (IL)-6/IL-13 activated JAK2 and STAT3, inducing epithelial to mesenchymal and fibroblast to myofibroblast transitions. Dual p-JAK2/p-STAT3 inhibition with JSI-124 or silencing of JAK2 and STAT3 genes suppressed ATII and the fibroblast to myofibroblast transition, with greater effects than the sum of those obtained using JAK2 or STAT3 inhibitors individually. Dual rather than single inhibition was also more effective for inhibiting fibroblast migration, preventing increases in fibroblast senescence and Bcl-2 expression, and ameliorating impaired autophagy. In rats administered JSI-124, a dual inhibitor of p-JAK2/p-STAT3, at a dose of 1 mg/kg/day, bleomycin-induced lung fibrosis was reduced and collagen deposition in the lung was inhibited, as were JAK2 and STAT3 activation and several markers of fibrosis, autophagy, senescence, and anti-apoptosis. CONCLUSIONS: JAK2 and STAT3 are activated in IPF, and their dual inhibition may be an attractive strategy for treating this disease.

Use of cyanoacrylate adhesives in general surgery.

This paper presents a review of the use of cyanoacrylate adhesives (CA) in general surgery and digestive surgery, studies the mechanisms of action and interactions of CAs in adherent tissues, and compiles data on the latest experimental and clinical applications. More than seven million traumatic injuries are estimated to occur every year, and between 26 and 90 million surgical procedures using different techniques are performed to close the resulting wounds. Traditional methods not only are both useful and effective, but also have some drawbacks. This review covers a considerable number of surgical procedures for which CAs had satisfactory results. The adhesive facilitated the healing of very diverse tissues, such as solid organs, vascular tissue or the abdominal wall. In other cases, no significant differences were found when CA was compared to traditional methods, with the adhesive standing out as a simple and reliable solution. The number of procedures in which CA was detrimental was very low. This review also collects and describes these. In conclusion, the surgical fields and procedures in which CA was successfully used are highly diverse. This review will allow physicians to determine which techniques were first used experimentally, but finally settled in clinical practice as feasible alternatives to standard treatments.